A carregar...
Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
BACKGROUND: The first‐line standard treatment of non‐small cell lung cancer (NSCLC) with EGFR mutation is EGFR‐tyrosine kinase inhibitors (TKIs). However, most patients will develop acquired resistance after 9–13 months. This study investigated novel molecular mechanisms of acquired resistance to EG...
Na minha lista:
| Publicado no: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons Australia, Ltd
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7180561/ https://ncbi.nlm.nih.gov/pubmed/32163227 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13342 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|